DnaK Therapeutics
01 / NewsroomAnnouncements and publications

What we have published, and what we have said.

Ten peer-reviewed papers between 2018 and 2026, three of them in PNAS, and every announcement the company has made.

Announcements

Announcement · 1 September 2026

DnaK Therapeutics & GATC Health Forge A Partnership To Evaluate, Accelerate & Prioritize Cancer Drug Candidates Using AI Platform

The collaboration will utilize predictive artificial intelligence for identifying the most promising molecules from an expansive pipeline that will substantially accelerate proof of concept timelines and markedly reduce capital costs associated with preclinical studies.

TAMPA, Fla. and IRVINE, Calif., Sept. 01, 2026 — DnaK Therapeutics and GATC Health Corp jointly announced today a collaboration to use GATC’s proprietary artificial intelligence platform to evaluate and prioritize 16 innovative, potential cancer drug candidates.

Distributed via GLOBE NEWSWIRE · Source: GATC Health Corp.

Read the full release

By applying GATC’s predictive AI platform early in the drug-development process, DnaK will be able to prioritize the most promising molecules for preclinical studies, obviating months off traditional experimental timelines and saving millions of dollars in research and development costs.

DnaK Therapeutics is pioneering potential treatments that target DnaK, a protein produced by tumor-associated bacteria that cause chemotherapy resistance in colorectal and gastric cancers, among others. The Company is investigating drug candidates that could consequently and substantially improve the effectiveness of existing cancer treatments by blocking or inhibiting DnaK.

“Drug development requires difficult decisions early in the process about where to invest time and resources. The earlier we can provide useful information about a candidate’s potential risks and benefits, the better those decisions can be before substantial resources are committed to laboratory studies and clinical development. We are honored and excited to have the opportunity to work with Dr. Gallo, one of the world’s most accomplished and renowned scientists, and the visionary leadership team of DnaK.” Dr. Rahul Gupta, president of GATC Health and former director of the White House Office of National Drug Control Policy
“We have a number of potentially viable drug candidates, but we need to determine which are the most beneficial, effective, and safest before we invest substantial resources. If this technology can give us useful information earlier and help us focus on the most promising candidates, it could considerably accelerate bringing these potentially groundbreaking drugs to the next stage of our research.” Dr. Robert C. Gallo, co-founder of DnaK Therapeutics

GATC will evaluate DnaK’s 16 potential drug candidates using its predictive AI technology and Derisq™ reports, which assess factors including potential safety, efficacy and off-target effects. The analysis will help identify a smaller group of high-priority candidates for experimental testing, with initial results expected this fall. DnaK will use those findings as it works toward selecting a lead development candidate. If successful, DnaK and GATC expect to explore opportunities to apply the approach to additional drug targets and therapeutic programs.

In January 2025, DnaK Therapeutics was accepted into the University of South Florida’s USF CONNECT’s Tampa Bay Technology Incubator (TBTI). Through TBTI, DnaK has access to specialized facilities, shared laboratory resources, mentorship, business development support and connections designed to help move research toward commercialization.

About DnaK Therapeutics

Founded in 2024 by Dr. Robert C. Gallo, Dr. Davide Zella, and Dr. Francesca Benedetti, DnaK Therapeutics develops selective small-molecule inhibitors of bacterial DnaK, a chaperone protein produced by tumor-associated bacteria that is linked to colorectal and gastric cancers and chemotherapy resistance. Based at USF Connect in Tampa, Florida, and supported by a research grant from the Florida Department of Health, the company is advancing a therapeutic program alongside a companion diagnostic to measure DnaK in tumors and identify patients most likely to benefit from treatment.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit gatchealth.com.

Media contacts

DnaK Therapeutics, Dipak Thakker, dipak@stellarit.com
GATC Health, Amanda Rice, arice@lifescicomms.com

02 / Publications2018 to 2026 · ten papers
PublicationJune 2026 · Int J Biol Macromol

DnaK unmasked: potential contributions of intrinsic disorder to the hijacking of human proteostasis by a bacterial chaperone

Bacterial DnaK and the human proteins it binds are unusually disordered, which is what lets one chaperone engage so many different human pathways.

DOI →
PublicationMarch 2024 · J Transl Med

Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU

Shows directly that bacterial DnaK weakens two of the most widely used chemotherapy drugs.

DOI →
PublicationFebruary 2024 · PNAS

Mycoplasma DnaK expression increases cancer development in vivo upon DNA damage

In animals, expressing bacterial DnaK sped up cancer development after DNA was damaged.

DOI →
PublicationJuly 2023 · PNAS

Mycoplasma DnaK increases DNA copy number variants in vivo

Bacterial DnaK caused genetic instability on its own, raising copy number variation in living animals.

DOI →
PublicationOctober 2022 · Front Microbiol

Characterization of the interactome profiling of Mycoplasma fermentans DnaK in cancer cells reveals interference with key cellular pathways

Maps which human proteins bacterial DnaK binds and which pathways it disrupts.

DOI →
PublicationApril 2021 · Int J Mol Sci

Analysis of DnaK Expression from a Strain of Mycoplasma fermentans in Infected HCT116 Human Colon Carcinoma Cells

How bacterial DnaK behaves once it is inside infected human colon cancer cells.

DOI →
PublicationFebruary 2021 · J Transl Med

Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines

DnaK introduced from outside the cell changed signaling activity inside human cancer cells.

DOI →
PublicationSeptember 2020 · Microorganisms

Mycoplasmas–host interaction: mechanisms of inflammation and association with cellular transformation

A review of how Mycoplasma species drive inflammation and transformation in host cells.

DOI →
PublicationFebruary 2020 · Int J Mol Sci

Role of Mycoplasma Chaperone DnaK in Cellular Transformation

Identifies DnaK as the specific bacterial component responsible for transformation.

DOI →
PublicationDecember 2018 · PNAS

Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties

The paper the company is built on. Mycoplasma promotes cancer in living animals, and DnaK is the reason.

DOI →

Publication dates are the journal's date of record as indexed in PubMed. Author lists, abstracts and full text are available at each DOI.